Welireg's sNDA for advanced PPGL treatment is under FDA priority review, potentially becoming the first U.S. therapy for this condition. The LITESPARK-015 trial supports the sNDA with ORR and DOR data ...

1 Day SNDA -1.84% DJIA -0.32% Russell 2K -0.30% Health Care/Life Sciences -0.52% ...

Scilex (SCLX) announced that it will be filing today of a Supplemental New Drug Application, SNDA, with the FDA for ELYXYB in acute pain indication. “We are well positioned to broaden the ELYXYB ...

At Sonida Senior Living, a filing with the SEC revealed that on Friday, Michael Simanovsky bought 42,111 shares of SNDA, at a cost of $21.32 each, for a total investment of $897,835. So far ...